To understand the mechanisms through which therapies targeting APOC3 could prevent CAD, this multivariable MR study evaluated the association of genetically predicted APOC3, using PCSK9 as a comparator, with CAD and lipoprotein-lipid particle parameters as biomarkers of mediation. This evidence concerns the gene PCSK9 and coronary artery disorder.